Arterial stiffness in chronic inflammation

Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases

Volumn 9781447151982, Issue , 2014, Pages 435-444

  Mäki Petäjä, Kaisa M ^a   McEniery, Carmel M ^a   Franklin, Stanley S ^b   Wilkinson, Ian B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammatory therapy; Arterial stiffness; Chronic inflammatory disease; Inflammation; Pulse wave velocity; Rheumatoid arthritis; Vascular inflammation

Indexed keywords

EID: 84949175669     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-5198-2_35     Document Type: Chapter

References (74)

1. Libby P. Infl ammation in atherosclerosis. Nature. 2002; 420(6917): 868-74
2. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331(7): 417-24
3. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of fi rst cardiovascular events. N Engl J Med. 2002; 347(20): 1557-65
4. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37(4): 481-94
5. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001; 44(12): 2737-45
6. Knight JS, Kaplan MJ. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol. 2013; 25(5): 597-605
7. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and metaanalysis. J Invest Dermatol. 2013; 133(10): 2340-6
8. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005; 2(1): 8-11
9. Hancock AT, Mallen CD, Belcher J, Hider SL. Association between polymyalgia rheumatica and vascular disease: a systematic review. Arthrit Care Res (Hoboken). 2012; 64(9): 1301-5
10. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999; 100(21): 2124-6
11. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-Analysis. J Am Coll Cardiol. 2010; 55(13): 1318-27
12. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25(5): 932-43
13. O'Rourke MF, Nichols WW. Aortic diameter, aortic stiffness, and wave refl ection increase with age and isolated systolic hypertension. Hypertension. 2005; 45(4): 652-8
14. Schmitt M, Avolio A, Qasem A, McEniery CM, Butlin M, Wilkinson IB, et al. Basal NO locally modulates human iliac artery function in vivo. Hypertension. 2005; 46(1): 227-31
15. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension. 2006; 48(4): 602-8
16. McEniery CM, Spratt M, Munnery M, Yarnell J, Lowe GD, Rumley A, et al. An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. Hypertension. 2010; 56(1): 36-43
17. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27(21): 2588-605
18. Currie CJ, Poole CD, Conway P. Evaluation of the association between the fi rst observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart. 2008; 94(4): 457-62
19. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscl Throm Vas Biol. 2004; 24(5): 969-74
20. Schumacher W, Cockcroft J, Timpson NJ, McEniery CM, Gallacher J, Rumley A, et al. Association between C-reactive protein genotype, circulating levels, and aortic pulse wave velocity. Hypertension. 2009; 53(2): 150-7
21. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009; 302(1): 37-48
22. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, et al. Acute systemic infl ammation increases arterial stiffness and decreases wave refl ections in healthy individuals. Circulation. 2005; 112(14): 2193-200
23. Wallace SM, Maki-Petaja KM, Cheriyan J, Davidson EH, Cherry L, McEniery CM, et al. Simvastatin prevents infl ammation-induced aortic stiffening and endothelial dysfunction. Br J Clin Pharmacol. 2010; 70(6): 799-806
24. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of infl ammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheum. 1999; 26(12): 2562-71
25. Maki-Petaja KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-Alpha therapy. Circulation. 2006; 114(11): 1185-92
26. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, et al. Arterial stiffness in chronic infl ammatory diseases. Hypertension. 2005; 46: 1-6
27. Booth AD, Wallace S, Yasmin, Jayne DR, Brown J. Infl ammation and arterial stiffness in systemic vasculitis: a model of vascular infl ammation. Arthritis Rheum. 2004; 50(2): 581-8
28. Schillaci G, De Socio GV, Pucci G, Mannarino MR, Helou J, Pirro M, et al. Aortic stiffness in untreated adult patients with human immunodefi ciency virus infection. Hypertension. 2008; 52(2): 308-13
29. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175(12): 1259-65
30. Zanoli L, Cannavo M, Rastelli S, Di PL, Monte I, Di GM, et al. Arterial stiffness is increased in patients with infl ammatory bowel disease. J Hypertens. 2012; 30(9): 1775-81
31. Yiu KH, Yeung CK, Chan HT, Wong RM, Tam S, Lam KF, et al. Increased arterial stiffness in patients with psoriasis is associated with active systemic infl ammation. Br J Dermatol. 2011; 164(3): 514-20
32. Schillaci G, Bartoloni E, Pucci G, Pirro M, Settimi L, Alunno A, et al. Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. Ann Rheum Dis. 2012; 71(7): 1151-6
33. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system?. Postgrad Med J. 1994; 70(830): 863-70
34. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol. 2001; 30(5): 305-7
35. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinfl ammatory drugs after acute myocardial infarction. Circulation. 2006; 113(25): 2906-13
36. Pieringer H, Stuby U, Hargassner S, Biesenbach G. Treatment with corticosteroids reduces arterial stiffness in patients with polymyalgia rheumatica as measured with pulse wave analysis. Ann Rheum Dis. 2008; 67(2): 279
37. Wong M, Jiang BY, McNeill K, Farish S, Kirkham B, Chowienczyk P. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol. 2007; 36(4): 265-9
38. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-Alpha antagonists improve aortic stiffness in patients with infl ammatory arthropathies: a controlled study. Hypertension. 2010; 55(2): 333-8
39. Doornum SV, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford). 2005; 44: 1428-32
40. Pieringer H, Stuby U, Pohanka E, Biesenbach G. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin Rheumatol. 2010; 29(7): 723-7
41. Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M. No signifi cant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford). 2013; 52(1): 204-9
42. Maki-Petaja KM, Wilkinson IB. Anti-infl ammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des. 2009; 15(3): 290-303
43. Tomochika Y, Okuda F, Tanaka N, Wasaki Y, Tokisawa I, Aoyagi S, et al. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996; 16(8): 955-62
44. Muramatsu J, Kobayashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMGCoA reductase inhibitor pravastatin. Atherosclerosis. 1997; 130(1-2): 179-82
45. Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes AD, Stanton A, et al. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid- Lowering Arm (CAFE-LLA) Study. Circulation. 2009; 119(1): 53-61
46. Wallace SM, Yasmin, McEniery CM, Maki-Petaja KM, Booth AD, Cockcroft JR, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007; 50(1): 228-33
47. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic infl ammation impairs endothelium-dependent dilatation in humans. Circulation. 2000; 102(9): 994-9
48. Gunnett CA, Lund DD, McDowell AK, Faraci FM, Heistad DD. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Thromb Vasc Biol. 2005; 25(8): 1617-22
49. Fichtlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher AM. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J. 2004; 25(16): 1412-8
50. Xu J, Xie Z, Reece R, Pimental D, Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase- derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol. 2006; 26(12): 2688-95
51. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-defi cient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001; 103(9): 1282-8
52. Kinoshita H, Tsutsui M, Milstien S, Katusic ZS. Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone. Prog Neurobiol. 1997; 52(4): 295-302
53. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S. Activation of the immune system and infl ammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2002; 29(5): 875-82
54. Savage CO, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol. 1992; 141(2): 335-42
55. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res. 1983; 24(8): 1070-6
56. Yasmin, Wallace S, McEniery CM, Dakham Z, Pusalkar P, Maki-Petaja K, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25(2): 372
57. Yasmin, McEniery CM, O'Shaughnessy KM, Harnett P, Arshad A, Wallace S, et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol. 2006; 26(8): 1799-805
58. Martyn CN, Greenwald SE. Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension. Lancet. 1997; 350(9082): 953-5
59. Moe SM, Chen NX. Infl ammation and vascular calcifi cation. Blood Purif. 2005; 23(1): 64-71
60. Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant. 2010; 25(6): 1853-8
61. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, et al. The circulating calcifi cation inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcifi cation in children on dialysis. Nephrol Dial Transplant. 2008; 23(10): 3263-71
62. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002; 8(11): 1249-56
63. Raines EW. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol. 2000; 81(3): 173-82
64. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother. 2003; 57(5-6): 195-202
65. Kaji T, Hiraga S, Yamamoto C, Sakamoto M, Nakashima Y, Sueishi K, et al. Tumor necrosis factor alpha-induced alteration of glycosaminoglycans in cultured vascular smooth-muscle cells. Biochim Biophys Acta. 1993; 1176(1-2): 20-6
66. Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem. 2002; 277(7): 4593-6
67. Chai S, Chai Q, Danielsen CC, Hjorth P, Nyengaard JR, Ledet T, et al. Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ Res. 2005; 96(5): 583-91
68. Li D, Fayad ZA, Bluemke DA. Can contrast-enhanced cardiac magnetic resonance assess infl ammation of the coronary wall?. JACC Cardiovasc Imaging. 2009; 2(5): 589-91
69. Watts RA, Mooney J, Lane SE, Scott DG. Rheumatoid vasculitis: becoming extinct?. Rheumatology (Oxford). 2004; 43(7): 920-3
70. Gravallese EM, Corson JM, Coblyn JS, Pinkus GS, Weinblatt ME. Rheumatoid aortitis: a rarely recognized but clinically signifi cant entity. Medicine (Baltimore). 1989; 68(2): 95-106
71. Hollan I, Prayson R, Saatvedt K, Almdahl SM, Nossent HC, Mikkelsen K, et al. Infl ammatory cell infi ltrates in vessels with different susceptibility to atherosclerosis in rheumatic and nonrheumatic patients: a controlled study of biopsy specimens obtained at coronary artery surgery. Circ J. 2008; 72(12): 1986-92
72. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013; 12(10): 1004-15. Ref Type: Journal (Full)
73. Maki-Petaja KM, Elkhawad M, Cheriyan J, Joshi FR, Ostor AJK, Hall FC, et al. Anti-tumor factor-A therapy reduces aortic infl ammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012; 126(21): 2473-80. Ref Type: Journal (Full)
74. Fayad ZA, Greenberg JD, Bucerius J. Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis. Circulation. 2012; 126(21): 2449-51